×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
GERN – geron corporation (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
GERN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/19
11:07 am
gern
Geron: Minimal Sales Growth But A Potential Run-Up Ahead [Seeking Alpha]
Medium
Report
Geron: Minimal Sales Growth But A Potential Run-Up Ahead [Seeking Alpha]
3/18
04:05 pm
gern
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neutral
Report
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/17
01:50 am
gern
Geron Details RYTELO Growth Plan, $220M-$240M 2026 Sales Guide and MF Trial Catalyst at Barclays Conference [Yahoo! Finance]
Low
Report
Geron Details RYTELO Growth Plan, $220M-$240M 2026 Sales Guide and MF Trial Catalyst at Barclays Conference [Yahoo! Finance]
3/12
05:34 am
gern
Geron Corporation (GERN) Reports Q4 EPS of (5c) [Yahoo! Finance]
Low
Report
Geron Corporation (GERN) Reports Q4 EPS of (5c) [Yahoo! Finance]
3/10
05:21 pm
gern
Geron Corporation (GERN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
Low
Report
Geron Corporation (GERN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
3/10
02:34 pm
gern
How The Geron (GERN) Story Is Shifting After Target Cut And New Equity Plans [Yahoo! Finance]
Low
Report
How The Geron (GERN) Story Is Shifting After Target Cut And New Equity Plans [Yahoo! Finance]
3/3
09:23 am
gern
Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone [Globe and Mail, The (Toronto, Canada)]
Medium
Report
Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone [Globe and Mail, The (Toronto, Canada)]
3/3
09:00 am
gern
Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone
Medium
Report
Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/3
04:33 pm
gern
Form SCHEDULE 13G GERON CORP Filed by: Soleus Capital Master Fund, L.P.
Low
Report
Form SCHEDULE 13G GERON CORP Filed by: Soleus Capital Master Fund, L.P.
3/2
07:11 am
gern
Form 10-K GERON CORP For: Dec 31
Medium
Report
Form 10-K GERON CORP For: Dec 31
2/25
07:15 am
gern
Form 8-K GERON CORP For: Feb 25
Medium
Report
Form 8-K GERON CORP For: Feb 25
2/19
06:11 pm
gern
Form 4 GERON CORP For: Feb 17 Filed by: Eid Joseph
Low
Report
Form 4 GERON CORP For: Feb 17 Filed by: Eid Joseph
2/19
06:10 pm
gern
Form 4 GERON CORP For: Feb 17 Filed by: ROBERTSON MICHELLE
Low
Report
Form 4 GERON CORP For: Feb 17 Filed by: ROBERTSON MICHELLE
2/13
08:45 am
gern
Form SCHEDULE 13G/A GERON CORP Filed by: Deep Track Capital, LP
Low
Report
Form SCHEDULE 13G/A GERON CORP Filed by: Deep Track Capital, LP
1/12
08:00 am
gern
Form 8-K GERON CORP For: Jan 12
Medium
Report
Form 8-K GERON CORP For: Jan 12
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
9/30
Geron Announces Fast Track Designation Granted to Imetelstat for Relapsed/Refractory Myelofibrosis
13.6%
3/17 Geron Co. (NASDAQ: GERN) had its price target lowered by analysts at B. Riley from $4.00 to $3.50. They now have a "buy" rating on the stock. 10.5%
3/19 GERN FINAL DEADLINE - Bronstein, Gewirtz & Grossman, LLC Reminds Geron Corporation Investors of Class Action and Encourages Investors to Contact the Firm 10.2%
3/20 Geron Co. (NASDAQ: GERN) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $1.25 price target on the stock. 8.9%
10/10 Geron Announces First Patient Dosed in IMerge Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes 7.0%
1/13 Form 4 GERON CORP For: Jan 10 Filed by: O'Farrell Elizabeth G. 6.7%
3/12 Q4/2019 12/31/2019 EPS -0.150 ZacksConsensus -0.200 ActVsEst 0.050 - Beat 6.5%
8/15 Geron Co. (NASDAQ: GERN) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock. 6.1%
8/8 Geron Starts Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes 5.8%
3/20 HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Geron Corporation (GERN) Investors: Application Deadline 3 Days Away, Investors with Losses Encouraged to Contact Firm 5.8%
3/17 Geron Co. (NASDAQ: GERN) had its price target lowered by analysts at B. Riley from $4.00 to $3.50. They now have a "buy" rating on the stock. 10.5%
3/19 GERN FINAL DEADLINE - Bronstein, Gewirtz & Grossman, LLC Reminds Geron Corporation Investors of Class Action and Encourages Investors to Contact the Firm 10.2%
3/20 Geron Co. (NASDAQ: GERN) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $1.25 price target on the stock. 8.9%
10/10 Geron Announces First Patient Dosed in IMerge Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes 7.0%
1/13 Form 4 GERON CORP For: Jan 10 Filed by: O'Farrell Elizabeth G. 6.7%
3/12 Q4/2019 12/31/2019 EPS -0.150 ZacksConsensus -0.200 ActVsEst 0.050 - Beat 6.5%
8/15 Geron Co. (NASDAQ: GERN) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock. 6.1%
8/8 Geron Starts Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes 5.8%
3/20 HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Geron Corporation (GERN) Investors: Application Deadline 3 Days Away, Investors with Losses Encouraged to Contact Firm 5.8%
TOP News Decliners
5/16
Geron Provides Imetelstat Program Update
-9.8%
3/5 Geron to Announce Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020 -9.7%
9/3 Geron Co. (NASDAQ: GERN) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock. -7.6%
3/15 HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Geron Corporation (GERN) Investors: 8 Days Remain Until Application Deadline, Investors with Losses Encouraged to Contact Firm -7.3%
6/17 Geron Reports Two Imetelstat Data Presentations at European Hematology Association Annual Congress -6.4%
11/15 Edited Transcript of GERN earnings conference call or presentation 7-Nov-19 1:00pm GMT [Yahoo! Finance News] -5.1%
8/22 Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) -4.9%
12/19 Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) -4.7%
10/17 Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) -4.7%
1/30 The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Geron Corporation (GERN) -4.4%
3/5 Geron to Announce Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020 -9.7%
9/3 Geron Co. (NASDAQ: GERN) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock. -7.6%
3/15 HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Geron Corporation (GERN) Investors: 8 Days Remain Until Application Deadline, Investors with Losses Encouraged to Contact Firm -7.3%
6/17 Geron Reports Two Imetelstat Data Presentations at European Hematology Association Annual Congress -6.4%
11/15 Edited Transcript of GERN earnings conference call or presentation 7-Nov-19 1:00pm GMT [Yahoo! Finance News] -5.1%
8/22 Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) -4.9%
12/19 Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) -4.7%
10/17 Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) -4.7%
1/30 The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Geron Corporation (GERN) -4.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: